Cantor Fitzgerald initiated coverage on Sensei Biotherapeutics
$SNSE
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Sensei Biotherapeutics with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2026 | Overweight | Cantor Fitzgerald | |
| 5/22/2026 | $55.00 | Buy | Citigroup |
| 4/20/2026 | $50.00 | Outperform | Leerink Partners |
| 6/2/2025 | $5.00 | Buy | H.C. Wainwright |
| 5/14/2024 | $5.00 | Overweight | Stephens |
| 3/10/2022 | $12.00 → $10.00 | Overweight | Piper Sandler |
| 7/1/2021 | $12.00 | Buy → Hold | Berenberg |
| 6/29/2021 | $30.00 → $14.00 | Outperform → Perform | Oppenheimer |
Cantor Fitzgerald initiated coverage of Sensei Biotherapeutics with a rating of Overweight
Citigroup initiated coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $55.00
Leerink Partners initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $50.00
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors," said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. "This acquisition and injection of new capital will
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead program after the company acquired Faeth Therapeutics in February 2026.
SCHEDULE 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
10-K/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
S-3/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i